At-home dosing and administration
The NUCALA Autoinjector for at-home administration.
12-week, open-label study assessed the correct use of the NUCALA Autoinjector in patients aged ≥12 years with severe eosinophilic asthma (n=104). NUCALA was administered as one 100-mg subcutaneous injection every 4 weeks by the patient or caregiver after being trained on proper technique with the Autoinjector at baseline. Successful use was determined by investigator observation using a checklist of steps based on Instructions for Use and visually inspecting the Autoinjector following the third dose. Ease of use and convenience of use at home were measured at study end on a 5-point scale (not at all, a little, moderately, very, and extremely) in the 102 patients with successful use.1,2
Administration of NUCALA with a single-use Autoinjector or 100 mg/mL prefilled syringe